0.92 (-%)
As of Oct 30, 2024
Source:
Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Our two most advanced clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead indication. DSTAT is in Phase 3 development as a potential first-line therapy in combination with standard chemotherapy for the treatment of acute myeloid leukemia (AML).
Country | United States |
Headquarters | durham, north carolina |
Phone Number | 919.806.1074 |
Industry | manufacturing |
CEO | Michael A. Sherman |
Website | www.chimerix.com |